Graham Home Care Limited has been acquired by Carewatch Care Services Limited
Graham Home Care, a domiciliary care business has been sold to Carewatch Care Services Limited, who are backed by Lyceum Capital, for an undisclosed consideration.
Graham Home Care was formed in 1996 to provide home based social care services. From that small beginning, Graham Home Care has grown significantly becoming the largest and most established Carewatch franchisee in the UK with nine franchises.
Oaklins Smith & Williamson, based in the UK, acted as corporate finance, accounting and tax advisors to Graham Home Care. The team's specialist commented: “There has been considerable activity in the care sector market recently and this was another transaction we have been pleased to work on. Graham Home Care has been a long term client of ours and we are delighted to have helped Sally and her father move onto the next stage of their lives.”
Talk to the deal team
Related deals
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Learn morebioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Learn moreSLT has been acquired by Indutrade
SLT S.r.l. has been acquired by Indutrade AB and will be integrated into the group’s life science business area. The transaction is Indutrade’s fifth acquisition in 2025 and is expected to have a marginally positive impact on the group’s earnings per share.
Learn more